Happy Valley Regeneration

Menu

Research Summaries​

Research Summaries

These studies are provided for educational purposes only. This does not constitute medical advice or claims that Happy Valley Regeneration treats, cures, or prevents these conditions. Stem cell therapies administered by Happy Valley Regeneration are investigational and not FDA-approved. Individual results vary and are not guaranteed.

Explore the transformative potential of stem cell therapies across a spectrum of conditions. Our curated clinical evidence showcases the latest research and real-world applications, providing insights into how regenerative medicine is reshaping patient care.

Below is a sample of existing clinical evidence

“Transplantation of stem cells has shown promise for improving functional recovery for Alzheimer’s disease. MSCs could promote survival, increased the metabolic activity and help to rescue the AD (Alzheimer’s Disease) cell model in vitro.”

Source:
“Alzheimer’s Disease and Stem Cell Therapy,” Choi et al, Experimental Neurobiology, 2014

“Analysis of different indicators of chronic inflammation and aging included in initial, 24-hours, 2 weeks and 3 months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions. Moreover, data from follow-up protocols demonstrate significant improvement in energy level, hair, nail growth and skin conditions… Intravenously administered UC-MSCs were safe and effective in the improvement of symptoms related to chronic inflammation.”

Source:
“Evaluation of immune response to intravenously administered human cord blood stem cells in the treatment of symptoms related to chronic inflammation,” Mehling et al., Journal of Stem Cell Research & Therapy, 2015

“hMSC (human Mesenchymal Stem Cell) infusions decreased ECM (Extracellular Matrix) deposition as evidenced by decreases in soluble and insoluble collagen production… hMSCs participate in improved outcomes of remodeling by reversing excess collagen deposition and changing hyaluronan levels.”

Source:
“Chronic asthma and Mesenchymal stem cells: Hyaluronan and airway remodeling,” Goldstein et al, Journal of Inflammation, 2017

“A single systemic injection of hMSCs (human Mesenchymal Stem Cells) into the tail vein was able to reduce NP-like behaviors and to modify molecular and cellular pain-associated pathways… hMSCs were able to reduce pain-like behaviors, such as mechanical allodynia and thermal hyperalgesia, once injected into the tail vein. An anti-nociceptive effect was detectable from day 11 post surgery (7 days post cell injection). hMSCs were mainly able to home in the spinal cord and pre-frontal cortex of neuropathic mice.”

Source:
“Long lasting effects of hMSC systemic administration on pain-like behaviors, cellular & biomolecular modificaiton in neuropathic mice,” Siniscalco et al, Frontiers in Integrative Neuroscience, 2011

“After UC-MSC (umbilical cord mesenchymal stem cells) infusion, steroid dosage significantly decreased and the patients’ conditions were also improved significantly.”

Source:
“Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial,” Zhang et al, Gut and Liver, 2018

“The results demonstrate the feasibility and safety of the allogeneic MSCs treatment while providing indications for their efficacy for relief of chronic low back pain… The procedure results in significant relief of pain and disability, and quantitative MRI evidence suggests partial disc healing.”

Source:
“Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial,” Noriega et al, Transplantation, 2017

“Mesenchymal stem cells (MSC) are significantly renoprotective after ischemia-reperfusion
injury… MSC attached in the renal microvascular circulation significantly decreased
apoptosis of adjacent cells… These data demonstrate that the unique vasculotropic,
paracrine actions elicited by MSC play a significant renoprotective role after AKI (Acute
Kidney Injury).”

Source:
“Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to
the recovery from acute kidney injury,” Tögel et al, American Journal of
Physiology–Renal Physiology, 2007

“Allogeneic UC MSCs (umbilical cord mesenchymal stem cells) were infused intravenously
on days 0 and 7… no transplantation-related adverse events were observed. 32.5% of
patients achieved MCR (major clinical response), 27.5% achieved PCR (partial clinical
response) during 12 months of follow up.”

Source:
“Umbilical cord mesenchymal stem cell transplantation in active and refractory
systemic lupus erythematosus: a multicenter clinical study,” Wang et al,
Arthritis Research & Therapy, 2014

“Animals received syngeneic MSCs (1×106 cells) by tail vein at an age before major photoreceptor loss… both rod and cone photoreceptors were preserved (5–6 cells thick) at the time when control animal has a single layer of photoreceptors remained; Visual function was significantly preserved compared with controls… The number of pathological vascular complexes (abnormal vessels associated with migrating pigment epithelium cells) and area of vascular leakage that would ordinarily develop were dramatically reduced… There was an increase in neurotrophic factors within eyes of animals that received MSCs.”
Source: “Non-Invasive Stem Cell Therapy in a Rat Model for Retinal Degeneration and Vascular Pathology,” Wang et al, PLOS ONE, 2010
“Four women with long histories of migraine or frequent tension-type headache that meet the International Classification of Headache Disorders criteria for Chronic Migraine or Tension-type Headaches… Two of the four patients, both of whom are Arab women aged 40 and 36 years, ceased having migraines after 1 month, for a period of 12 to 18 months. The third patient, a Slavic woman aged 43 years, had a significant decrease in the frequency and severity of migraines with only seven migraines over 18 months. The fourth patient, an Asian woman aged 44 years, obtained a temporary decrease for a period of a month and was retreated 18 months later and has been free of migraines to date for 1 month”
Source: “Migraine and tension-type headache treated with stromal vascular fraction: a case series,” Bright et al, Journal of Medical Case Reports, 2014
“Among the eight cases, six showed therapeutic improvement after hUC-MSCs treatment, and in all eight patients, relapse frequencies decreased to 36.4% of those before the treatment… MRI characteristics also showed decreased volume and severity of lesions, with few adverse events… hUC-MSCs can alleviate disability and reduce relapse of secondary progressive multiple sclerosis by modulating immune responses, which also had been proved to be safe in MS patients.”
Source: “Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Secondary Progressive Multiple Sclerosis,” Lu et al, Stem Cell Research & Therapy, 2013

“In the MSC-treated joints, there was marked regeneration of the medial meniscus and decreased cartilage destruction and bone changes.”

Source:
“Mesenchymal stem cells in arthritic diseases,” Chen et al, Arthritis Research & Therapy, 2008

“At 6 weeks post-transplant two of four animals responded (decreased rotations by approximately 60%). At 12 weeks’ survival, three of four animals responded to the transplant (decreased rotations by approximately 60%). One animal in the 12-week survival group decreased rotations by 90%. In contrast, the PD (Parkinson’s Disease) animals that were not transplanted with UCMS (Umbilical Cord Matrix Stem) cells all showed a progressive degradation in performance following 6-OHDA.”
Source: “Human Umbilical Cord Matrix Stem Cells: Preliminary Characterization and Effect of Transplantation in a Rodent Model of Parkinson’s Disease,” Weiss, Stem Cells, 2006